Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) ...
Sep 1, 2023
0
0
Losing the activity of a key ion channel in the brain may contribute to the buildup of a devastating and toxic protein responsible for the clumps of plaque that accumulate in Alzheimer's disease, a team of neurobiologists ...
A new research perspective titled "CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies" has been published in Oncotarget.
Aug 9, 2023
0
1
Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30% of cases. When tumors are driven by the oncogene ALK—which ...
Aug 3, 2023
0
22
Despite the proliferation of novel therapies such as immunotherapy or targeted therapies, radiation and chemotherapy remain the frontline treatment for cancer patients. About half of all patients still receive radiation and ...
Jul 28, 2023
0
11
Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians ...
Jul 20, 2023
0
16
Tumor-initiating cells, or cancer stem cells, are gaining attention in cancer therapy, as they can travel through the body and cause cancerous tumors at other sites through metastasis. These cells also may cause resistance ...
Jul 5, 2023
0
0
The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.
Jun 27, 2023
0
1
With malaria becoming increasingly drug-resistant, a team of UCF researchers is looking to use cancer drugs to accelerate the discovery of new life-saving therapies for the disease.
Jun 21, 2023
0
38
Ruxolitinib, a drug that is already approved by the U.S. Food and Drug Administration (FDA) for treating certain cancers and skin conditions, is effective at inhibiting CaMKII, a protein kinase linked to cardiac arrhythmias.
Jun 21, 2023
1
66
